Drug Profile
Insulin biosimilar - Biocon
Alternative Names: Insugen; Recombinant human insulin - Biocon; rh-Insulin - BioconLatest Information Update: 19 May 2023
Price :
$50
*
At a glance
- Originator Biocon
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diabetes mellitus
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for phase-I development in Diabetes-mellitus(In volunteers) in Germany (SC, Injection)
- 20 Jan 2020 Biocon completes a phase I trial in Diabetes mellitus (In healthy volunteers) in Germany (NCT04022291)
- 21 Dec 2019 Biocon completes a phase I trial in Diabetes mellitus (In volunteers) in Germany (NCT04022304)